Literature DB >> 8163650

Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides.

R Morishita1, G H Gibbons, K E Ellison, M Nakajima, H von der Leyen, L Zhang, Y Kaneda, T Ogihara, V J Dzau.   

Abstract

The cell cycle regulatory enzyme, cdk (cyclin-dependent kinase) 2 kinase, is activated in the rat carotid artery after balloon angioplasty injury, and may mediate smooth muscle proliferation. To test the hypothesis that inhibition of the expression of this key enzyme can inhibit intimal hyperplasia, we studied the effect of antisense phosphorothioate oligodeoxynucleotides (ODN) against cdk 2 kinase administered by intraluminal delivery using hemagglutinating virus of Japan (HVJ)-liposome-mediated transfer. The specificity of antisense cdk 2 ODN was confirmed by the observation that mRNA level of cdk 2 kinase in injured vessels was markedly diminished by the antisense ODN treatment. At 2 wk after transfection, antisense cdk 2 ODN treatment (15 microM) resulted in a significant inhibition (60%) in neointima formation, compared with sense ODN-treated and untreated vessels. Since we have previously observed that cell division cycle 2 kinase mRNA was also activated after vascular injury, we administered the combination of antisense cdc 2 and cdk 2 ODN in this study. Antisense cdc 2 ODN alone (15 microM) only reduced intimal formation by 40%. Combined antisense treatment resulted in near complete inhibition of neointima formation. To understand the mechanism of the sustained effect of a single antisense ODN administration, we examined kinetics of ODN in the vessel wall. Using phosphorothioate FITC-labeled ODN, we transfected carotid artery using the HVJ-liposome method. Fluorescence localized immediately to the medial layer, and persisted up to 2 wk after transfection. These results demonstrate that a single intraluminal administration of antisense ODN directed to cell cycle regulatory genes (e.g., cdk 2 kinase) using the HVJ method can result in a sustained inhibition of neointima formation after balloon angioplasty in rat carotid injury model.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8163650      PMCID: PMC294159          DOI: 10.1172/JCI117123

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  31 in total

1.  Association of cdk2 kinase with the transcription factor E2F during S phase.

Authors:  M Pagano; G Draetta; P Jansen-Dürr
Journal:  Science       Date:  1992-02-28       Impact factor: 47.728

2.  Role of platelets in smooth muscle cell proliferation and migration after vascular injury in rat carotid artery.

Authors:  J Fingerle; R Johnson; A W Clowes; M W Majesky; M A Reidy
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

3.  Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF.

Authors:  G A Ferns; E W Raines; K H Sprugel; A S Motani; M A Reidy; R Ross
Journal:  Science       Date:  1991-09-06       Impact factor: 47.728

4.  Intracellular distribution of microinjected antisense oligonucleotides.

Authors:  J P Leonetti; N Mechti; G Degols; C Gagnor; B Lebleu
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-01       Impact factor: 11.205

5.  The uptake kinetics of chimeric oligodeoxynucleotide analogues in human leukaemia MOLT-4 cells.

Authors:  D G Spiller; D M Tidd
Journal:  Anticancer Drug Des       Date:  1992-04

6.  Induction of insulin-like growth factor I messenger RNA in rat aorta after balloon denudation.

Authors:  B Cercek; M C Fishbein; J S Forrester; R H Helfant; J A Fagin
Journal:  Circ Res       Date:  1990-06       Impact factor: 17.367

7.  Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia.

Authors:  R Morishita; G H Gibbons; K E Ellison; M Nakajima; L Zhang; Y Kaneda; T Ogihara; V J Dzau
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-15       Impact factor: 11.205

8.  Isolation of the human cdk2 gene that encodes the cyclin A- and adenovirus E1A-associated p33 kinase.

Authors:  L H Tsai; E Harlow; M Meyerson
Journal:  Nature       Date:  1991-09-12       Impact factor: 49.962

9.  Negative regulation of G1 in mammalian cells: inhibition of cyclin E-dependent kinase by TGF-beta.

Authors:  A Koff; M Ohtsuki; K Polyak; J M Roberts; J Massagué
Journal:  Science       Date:  1993-04-23       Impact factor: 47.728

10.  Cyclin A is required at two points in the human cell cycle.

Authors:  M Pagano; R Pepperkok; F Verde; W Ansorge; G Draetta
Journal:  EMBO J       Date:  1992-03       Impact factor: 11.598

View more
  36 in total

Review 1.  Gene therapy for restenosis.

Authors:  R C Smith; K Walsh
Journal:  Curr Cardiol Rep       Date:  2000-01       Impact factor: 2.931

2.  Thymidine phosphorylase inhibits vascular smooth muscle cell proliferation via upregulation of STAT3.

Authors:  Hong Yue; Kuniyoshi Tanaka; Tatsuhiko Furukawa; Sadashiva S Karnik; Wei Li
Journal:  Biochim Biophys Acta       Date:  2012-06-02

Review 3.  DNA antisense strategies in the study of receptors for vasoactive peptides, and of growth and wound-healing factors.

Authors:  P D'Orléans-Juste; M G Sirois; E R Edelman; D Regoli; L H Pheng; G Bkaily; C J Lindsey
Journal:  Mol Cell Biochem       Date:  1997-07       Impact factor: 3.396

4.  Regulation of vascular smooth muscle cell growth: targeting the final common pathway.

Authors:  Angela M Taylor; Coleen A McNamara
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-10-01       Impact factor: 8.311

5.  Regulation of cellular proliferation and intimal formation following balloon injury in atherosclerotic rabbit arteries.

Authors:  R D Simari; H San; M Rekhter; T Ohno; D Gordon; G J Nabel; E G Nabel
Journal:  J Clin Invest       Date:  1996-07-01       Impact factor: 14.808

Review 6.  The cell cycle: a critical therapeutic target to prevent vascular proliferative disease.

Authors:  Thierry Charron; Nafiseh Nili; Bradley H Strauss
Journal:  Can J Cardiol       Date:  2006-02       Impact factor: 5.223

Review 7.  Current aspects of gene therapy: implications for vascular interventions.

Authors:  F Reifers; J Kreuzer
Journal:  J Mol Med (Berl)       Date:  1995-12       Impact factor: 4.599

8.  Expression of cell division cycle 2 kinase transcription in chronically rejected cardiac allografts of nonhuman primates.

Authors:  A Schoenbeck; M Isobe; J Suzuki; M Kato; N Kitazawa; J Amano; M Endoh; M Kawauchi; S Takamoto; M Sekiguchi
Journal:  Heart Vessels       Date:  1997       Impact factor: 2.037

9.  Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides.

Authors:  C Beltinger; H U Saragovi; R M Smith; L LeSauteur; N Shah; L DeDionisio; L Christensen; A Raible; L Jarett; A M Gewirtz
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

10.  Genetic engineering of vein grafts resistant to atherosclerosis.

Authors:  M J Mann; G H Gibbons; R S Kernoff; F P Diet; P S Tsao; J P Cooke; Y Kaneda; V J Dzau
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.